ReviewLung cancer (Amsterdam, Netherlands)2011
Do all lung adenocarcinomas follow a stepwise progression?
Review in Lung cancer (Amsterdam, Netherlands), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- The infiltration risk prediction models by logistic regression for ground-glass pulmonary nodules: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- [Advance in Diagnose and Treatment Strategies of Adenocarcinoma in Situ].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2017Pooled it
- Study of Imaging Analysis for Distinguishing Alveolar Collapse From Invasive Lesions in Early-Stage Lung Adenocarcinoma.Thoracic cancer · 2026Article
- Exploring the relationships between CT and pathological characteristics and gene mutations in neoplastic ground glass nodules.BMC medical imaging · 2025Article
- Effect of ground-glass opacity components on the recurrence of pathological stage IB non-small cell lung cancer harboring epidermal growth factor receptor mutations.Surgery today · 2025Article
- Article
- HER2 mutations in pulmonary adenocarcinoma presenting with ground-glass nodules.World journal of surgical oncology · 2025Article
- Article
- Validation of T stage classification strategy for >2 cm ground-glass opacity non-small cell lung cancer: a retrospective cohort study.Translational lung cancer research · 2024Article
- Genetic characteristics of lung adenocarcinoma with ground-glass opacity component.Journal of thoracic disease · 2023Article
- Diagnostic performance of RASSF1A and SHOX2 methylation combined with EGFR mutations for differentiation between small pulmonary nodules.Journal of cancer research and clinical oncology · 2023Article
- Advances in diagnosis and prediction for aggression of pure solid T1 lung cancer.Precision clinical medicine · 2023Article
- Artificial intelligence system-based histogram analysis of computed tomography features to predict tumor invasiveness of ground-glass nodules.Quantitative imaging in medicine and surgery · 2023Article
- Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2+ Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma.Cancer research · 2023Article
- Review
- Lepidic growth component as a favorable prognostic factor in non-small cell lung cancer of ≤3 cm.Thoracic cancer · 2022Article
- Ground glass opacity: can we correlate radiological and histological features to plan clinical decision making?General thoracic and cardiovascular surgery · 2022Observational
- Pan-Driver-Negatives versus Epidermal Growth Factor Receptor Mutants for C-Stage IA Lung Adenocarcinoma with Ground-Glass Opacity.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2022Article
- Updates in grading and invasion assessment in lung adenocarcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Similar to the adenoma-carcinoma sequence of colorectal cancer, lung adenocarcinoma is thought to follow a linear multistep progression, in which a precursor lesion progresses to adenocarcinoma in situ, which is followed by invasive adenocarcinoma. However, lung adenocarcinoma can no longer be considered as a single type of tumor but rather a group of distinct subsets of tumors that arise from different molecular pathways. Consistent with this concept, recent findings revealed that this linear progression might not occur in all lung adenocarcinomas. First, according to the molecular classification based on expression profiling, lung cancer can be divided into at least two subsets; precancerous and in situ lesions share characteristics of molecular expression and clinical features with only one of the two subsets, suggesting that the linear progression is only applicable to the subset in the molecular classification. Second, when EGFR and KRAS were examined based on the progression steps, the mutation rate of KRAS was disproportionally distributed; however, according to the progression schema, gene alterations should be evenly accumulated along the entire progression. Third, by means of comparative genomic hybridization analysis, some adenocarcinoma in situ revealed gene alterations discontinuous to invasive adenocarcinoma. Finally, there were some clinical observations that support that some lesions escape from the progression. In this review, we hypothesize a novel scenario for the progression of lung adenocarcinoma, which does not support a linear progression schema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.